
About this episode
Moderator: Kristian Steen Frederiksen (Copenhagen, Denmark)
Guest: Lutz Fröhlich (Mannheim, Germany)
The field of dementia and specifically the treatment of Alzheimer´s disease is at the brink of a possible new era in which disease-modifying therapy will become available in the form of anti-bodies directed against beta-amyloid.
Prof. Kristian Steen Frederiksen and Prof. Lutz Fröhlich kick off the June episodes on Dementia and Cognitive Disorderswith discussions on the background and development of anti-bodies directed against beta-amyloid development, status with regards to clinical trials in AD of anti-amyloid anti-body therapy, and challenges and opportunities in clinical practice if anti-amyloid anti-body therapy will be approved.
Get every episode summarized
Each time eanCast: Weekly Neurology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from eanCast: Weekly Neurology

Ep. 193: Understanding GBS and other inflammatory neuropathies across ages
eanCast: Weekly Neurology
Mar 22, 202628:21failed

Ep. 192: Movement disorders in children and adults: different or the same?
eanCast: Weekly Neurology
Mar 15, 202636:17failed

Ep. 191: FND in children and adults: different or the same?
eanCast: Weekly Neurology
Mar 8, 202639:06failed

Ep. 190: Parkinson’s disease – more than a movement disorder
eanCast: Weekly Neurology
Mar 1, 202620:29pending